Using Long-acting Injectable Cabotegravir and Rilpivirine to Improve Adherence with HIV-1 Treatment

Using Long-acting Injectable Cabotegravir and Rilpivirine to Improve Adherence with HIV-1 Treatment

Bibliographic Details
Main Author:	Dr. Chadane Thompson
Format:	Article
Language:	English
Published:	Trinidad and Tobago Medical Association (T&TMA) 2022-04-01
Series:	Caribbean Medical Journal
Online Access:	https://www.caribbeanmedicaljournal.org/2022/04/17/using-long-acting-injectable-cabotegravir-and-rilpivirine-to-improve-adherence-with-hiv-1-treatment/

Similar Items

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
by: Fernandez C, et al.
Published: (2019-07-01)

Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort
by: Michael G. Sension, et al.
Published: (2023-11-01)

Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine
by: Parul Patel, et al.
Published: (2023-12-01)

Real-life efficacy and satisfaction of long-acting ART Cabotegravir-Rilpivirine in HIV-infected individuals
by: S. Spampinato, et al.
Published: (2023-12-01)

Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial
by: Michael B. Wohlfeiler JD, MD, AAHIVS, et al.
Published: (2024-04-01)

Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
by: Santiago Moreno, et al.
Published: (2023-07-01)

Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
by: Ben Parker, et al.
Published: (2021-01-01)

Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study
by: Miranda Murray, et al.
Published: (2019-09-01)

Safety and efficacy of long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection: a systematic review and meta-analysis protocol
by: Xiaodi Li, et al.
Published: (2022-12-01)

Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine
by: Eisuke Adachi, et al.
Published: (2024-01-01)

Long-acting combination of cabotegravir plus rilpivirine: A picture of potential eligible and ineligible HIV-positive individuals from the Italian ARCA cohort
by: Adriana Cervo, et al.
Published: (2023-09-01)

Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland
by: Paul Thoueille, et al.
Published: (2022-07-01)

Could Long-Acting Cabotegravir-Rilpivirine Be the Future for All People Living with HIV? Response Based on Genotype Resistance Test from a Multicenter Italian Cohort
by: Andrea De Vito, et al.
Published: (2022-01-01)

Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in SwitzerlandResearch in context
by: Paul Thoueille, et al.
Published: (2024-01-01)

Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.
by: Deanna Kerrigan, et al.
Published: (2018-01-01)

Development and Validation of Stability Indicating RP-HPLC Method for the Simultaneous Determination of Cabotegravir and Rilpivirine in Bulk and Injection Dosage Form
by: A Suneetha, et al.
Published: (2022-12-01)

Method development and validation for Cabotegravir and Rilpivirine by using HPLC and its degradants are characterized by LCMS and FTIR
by: Anuradha Vejendla, et al.
Published: (2021-11-01)

Securing accelerated access to long‐acting injectable cabotegravir for HIV prevention in low‐ and middle‐income countries
by: Sarah Y. Jenkins, et al.
Published: (2023-07-01)

Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study
by: Beatriz Grinsztejn, et al.
Published: (2023-04-01)

Immune reconstitution inflammatory syndrome in AIDS patient after successful induction of virological suppression with cabotegravir/rilpivirine
by: Rami Al-Handola, et al.
Published: (2023-07-01)

Characterizing Lipid‐Coated Mesoporous Silica Nanoparticles as CD169‐Binding Delivery System for Rilpivirine and Cabotegravir
by: Han Zang, et al.
Published: (2022-05-01)

Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection
by: Vasiliki Chounta, et al.
Published: (2022-05-01)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
by: Dowers E, et al.
Published: (2018-11-01)

Multitasking Pharmacophores Support Cabotegravir-Based Long-Acting HIV Pre-Exposure Prophylaxis (PrEP)
by: Zheng Wan, et al.
Published: (2024-01-01)

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
by: Raphael J Landovitz, et al.
Published: (2018-11-01)

Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults
by: Wissam K. Kabbara, et al.
Published: (2015-09-01)

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
by: Steven J. Smith, et al.
Published: (2018-05-01)

Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection
by: Isabella C. Young, et al.
Published: (2023-02-01)

Dose-Ranging Plasma and Genital Tissue Pharmacokinetics and Biodegradation of Ultra-Long-Acting Cabotegravir In Situ Forming Implant
by: Isabella C. Young, et al.
Published: (2023-05-01)

Integrating long-acting injectable treatment to improve medication adherence among persons living with HIV and opioid use disorder: study protocol
by: Kirsten J. Langdon, et al.
Published: (2023-10-01)

Cabotegravir, the Long-Acting Integrase Strand Transfer Inhibitor, Potently Inhibits Human T-Cell Lymphotropic Virus Type 1 Transmission in vitro
by: Bethany S. Schneiderman, et al.
Published: (2022-04-01)

Author Correction: Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection
by: Isabella C. Young, et al.
Published: (2024-02-01)

Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
by: Nadia Galizzi, et al.
Published: (2018-01-01)

Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy
by: Lorie Benning, et al.
Published: (2020-07-01)

The role of rilpivirine in Southern Africa
by: Michelle A. Moorhouse, et al.
Published: (2019-05-01)

Quantum Mechanical-Based Stability Evaluation of Crystal Structures for HIV-Targeted Drug Cabotegravir
by: Yanqiang Han, et al.
Published: (2021-11-01)

Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study
by: Delphine Sculier, et al.
Published: (2017-07-01)

Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study
by: Rosario Palacios MD, PhD, et al.
Published: (2018-03-01)

Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection
by: Bernardini C, et al.
Published: (2013-06-01)

An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients
by: Putcharoen O, et al.
Published: (2013-09-01)